More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates
Authors:
Open Access
- 12 August 2022
- journal article
- review article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 27 (8) , 240
Abstract
Antibody drug conjugates (ADCs) are rapidly becoming a cornerstone in targeted therapies, especially for the treatment of cancer. Currently, there are 12 FDA-approved ADCs, eight of which have been approved within the last five years, with numerous candidates in clinical trials. The promising clinical perspective of ADCs has led to the development of not only novel conjugation techniques, but also antibody formats, linkers, and payloads. While the majority of currently approved ADCs relies on cytotoxic small molecule warheads, alternative modes of action imparted by novel payloads and non-classical antibody formats are gaining attention. In this review, we summarize the current state of the art of ADC technologies, as well as comprehensively examine alternative payloads, such as toxic proteins, cytokines, PROTACs and oligonucleotides, and highlight the potential of multi-specific antibody formats for the next generation of therapeutic antibody conjugates.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (16GW0358)
This publication has 268 references indexed in Scilit:
- A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumorsBMC Cancer, 2013
- An Anti‐PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and TherapyAdvanced Healthcare Materials, 2012
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences, 2012
- Site-specific chemical protein conjugation using genetically encoded aldehyde tagsNature Protocols, 2012
- Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting MoietiesJournal of Biological Chemistry, 2011
- Hydrogen Peroxide Activated Matrix Metalloproteinase Inhibitors: A Prodrug ApproachAngewandte Chemie International Edition, 2010
- Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal EntrapmentThe AAPS Journal, 2009
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008
- Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitroBritish Journal of Cancer, 2008
- Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1Proceedings of the National Academy of Sciences, 2007